Comments
A couple of key developments impacting the pharmaceutical industry come up in the next two weeks. The annual price revision that companies are allowed to make in line with the Wholesale Price Index will happen, in April. This time a downward revision (about – 2.75 per cent) is expected, a departure from the price hikes seen last year. The coming week will also see hearings on several cases filed in the Delhi High Court on the recent controversy over the 343-fixed doze combinations banned by the Health Ministry. A handful of companies have got interim stay orders from the court against the ban on their combination drugs. Monday will see the next hearing on these cases that affect Pfizer, Abbott, Glenmark, Alembic, Macleods, Procter & Gamble and Reckitt Benckiser.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.